|
Accueil > Actualité
AstraZeneca: CHMP recommends Imfinzi in lung cancer
(CercleFinance.com) - AstraZeneca announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has recommended approval of Imfinzi (durvalumab) in combination with chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence and without EGFR mutations or ALK rearrangements.
Based on the AEGEAN study, this decision was based on a 32% reduction in the risk of recurrence or death with this peri-operative treatment. Imfinzi also improved the pathological complete response rate and showed a favorable trend in overall survival. Imfinzi is already approved in the US and several other countries. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
21/05/2025 08:50
Eurazeoouverture d'une nouvelle adresse à Milan 21/05/2025 08:10 Eiffageplus de 57.000 salariés souscripteurs 21/05/2025 07:45 Genfitdéblocage d'un paiement d'étape sur Iqirvo 21/05/2025 07:20 Arkemaun placement d'obligations hybrides réalisé 20/05/2025 18:32 Vergnetvictoire judiciaire dans le dossier nigérien 20/05/2025 18:28 Saint-Gobainconstruction d'une nouvelle usine bas carbone Tous les articles sociétés |
